SpringWorks Therapeutics PE Ratio 2019-2022 | SWTX

Current and historical p/e ratio for SpringWorks Therapeutics (SWTX) from 2019 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. SpringWorks Therapeutics PE ratio as of May 27, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

SpringWorks Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-27 18.36 0.00
2022-03-31 56.44 $-4.22 0.00
2021-12-31 61.98 $-3.58 0.00
2021-09-30 63.44 $-2.19 0.00
2021-06-30 82.41 $-1.86 0.00
2021-03-31 73.57 $-1.36 0.00
2020-12-31 72.52 $-1.11 0.00
2020-09-30 47.67 $-1.74 0.00
2020-06-30 42.00 $-3.00 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.907B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00